These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23208714)

  • 1. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.
    Butterfield JM; Mueller BA; Patel N; Cardone KE; Grabe DW; Salama NN; Lodise TP
    Antimicrob Agents Chemother; 2013 Feb; 57(2):864-72. PubMed ID: 23208714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.
    Patel N; Cardone K; Grabe DW; Meola S; Hoy C; Manley H; Drusano GL; Lodise TP
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1677-83. PubMed ID: 21282429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.
    Cardone KE; Lodise TP; Patel N; Hoy CD; Meola S; Manley HJ; Drusano GL; Grabe DW
    Clin J Am Soc Nephrol; 2011 May; 6(5):1081-8. PubMed ID: 21393490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.
    Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment.
    Chaves RL; Chakraborty A; Benziger D; Tannenbaum S
    J Antimicrob Chemother; 2014 Jan; 69(1):200-10. PubMed ID: 24030545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.
    Bhavnani SM; Rubino CM; Ambrose PG; Drusano GL
    Clin Infect Dis; 2010 Jun; 50(12):1568-74. PubMed ID: 20462352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: Pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients.
    Ishii M; Orito Y; Shiomi M; Wrishko RE; Yoshitsugu H
    J Infect Chemother; 2023 Jun; 29(6):592-598. PubMed ID: 36868408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment.
    Menezes B; Alves I; Staudt K; Beltrame B; Michelin L; de Araújo BV; Tasso L
    Braz J Microbiol; 2021 Dec; 52(4):1967-1979. PubMed ID: 34337679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation.
    Olney KB; Howard JI; Burgess DS
    J Clin Pharmacol; 2024 Jul; 64(7):860-865. PubMed ID: 38497326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Falcone M; Russo A; Venditti M; Novelli A; Pai MP
    Clin Infect Dis; 2013 Dec; 57(11):1568-76. PubMed ID: 24046298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment.
    Moise PA; Amodio-Groton M; Rashid M; Lamp KC; Hoffman-Roberts HL; Sakoulas G; Yoon MJ; Schweitzer S; Rastogi A
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1192-200. PubMed ID: 23254428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.
    D'Avolio A; Pensi D; Baietto L; Pacini G; Di Perri G; De Rosa FG
    Drugs; 2016 Aug; 76(12):1161-74. PubMed ID: 27412121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin Pharmacokinetics and Pharmacodynamics in Patients on Methadone Substitution Therapy.
    De Gregori S; De Silvestri A; Molinaro MD; Monzillo V; Biscarini S; Colaneri M; Gallazzi I; Bartoli A; Bruno R; Seminari E
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):547-554. PubMed ID: 34231117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis.
    Yamada T; Ooi Y; Oda K; Shibata Y; Kawanishi F; Suzuki K; Nishihara M; Nakano T; Yoshida M; Uchida T; Katsumata T; Ukimura A
    J Infect Chemother; 2020 Apr; 26(4):379-384. PubMed ID: 31836287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation.
    Lewis SJ; Jang SM; Mueller BA
    BMC Nephrol; 2023 Sep; 24(1):270. PubMed ID: 37710245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.
    Haselden M; Leach M; Bohm N
    Ann Pharmacother; 2013 Oct; 47(10):1342-7. PubMed ID: 24259698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
    Sakoulas G; Rose W; Rybak MJ; Pillai S; Alder J; Moellering RC; Eliopoulos GM
    J Clin Microbiol; 2008 Jan; 46(1):220-4. PubMed ID: 18003803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.